Advertisement

Advertisement

HotelsFoodShoppingCoffeeGroceryGas

Signature Acquisitions

+1 (212) 470-5200
Website

Advertisement

Advertisement

20 Commerce Dr Ste 110
Cranford, NJ 07016
+1 (212) 470-5200
https://signatureacq.com

Signature Acquisitions, based in Cranford, NJ, is a leading real estate firm specializing in the acquisition and management of Class-A office buildings in the Northeast. With a portfolio of over $300 million in assets and 3 million square feet of space, the company has established a reputation for excellence, offering superior property management and a commitment to delivering the Signature experience.

With a focus on Suburban New Jersey and Long Island, Signature Acquisitions has strategically acquired and managed properties, shedding non-strategic assets to concentrate on Class-A office buildings. As a fully integrated owner, the company provides a range of services including asset acquisition, construction supervision, asset management, and brokerage and property services.

Generated from the website

Also at this address

Lerner David

Richel Family Foundation

TAL International Container Corporation

Somerset Marine Lines

Find related places

Financial Advisor

Financial Advisor

Own this business?
Claim it
See a problem?

You might also like

Goldman Sachs Securities Division
Business services, nec, nec, Services, nec, nec, Internal medicine practitioners

Goldman Sachs Securities Division

The Goldman Sachs Group is a leading global investment banking, securities and investment management firm that provides a wide range of services worldwide to a substantial and diversified client base that includes corporations, financial institutions, governments and high net-worth individuals. Founded in 1869, it is one of the oldest and largest investment banking firms. The firm offers an array of services, such as currencies and commodities, trading and capital markets, merchant banking, asset management, mutual funds and securities lending programs. The Goldman Sachs Group is headquartered in New York and maintains offices in London, Frankfurt, Tokyo, Hong Kong and other major financial centers throughout the world.
Enzon Pharmaceuticals, Inc

Enzon Pharmaceuticals, Inc

Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and other life-threatening diseases. The company s specialized sales force markets Abelcet, Oncaspar, Adagen and Depocyt in North America. In addition, it also receives royalties on sales of Peg-Intron, which is marketed by Schering-Plough Corporation, and Macugen, which is marketed by OSI Pharmaceuticals and Pfizer. The company s product-driven strategy includes a drug development program that leverages its proprietary technologies that includes a next-generation PEGylation platform that utilizes linkers designed to release compounds at a controlled rate. Internal research and development efforts are complemented with strategic initiatives, such as partnerships designed to broaden its revenue base or provide access to promising new technologies or product development opportunities. Enzon Pharmaceuticals is headquartered in Bridgewater, N.J.

TPC Acquisition LLC

TPC Acquisition LLC is a business located in Rahway, NJ that specializes in acquiring and managing various types of assets. With a focus on strategic investments, TPC Acquisition LLC navigates the market to identify opportunities for growth and development. Generated from their business information
United States›New Jersey›Cranford›Signature Acquisitions

Partial Data by Infogroup (c) 2024. All rights reserved.

Advertisement

Advertisement

  • Get directions
  • MapQuest Travel
  • Route Planner
  • Print your map
  • Get help
  • Search the web
  • Send feedback
Learn more about our mobile apps.
  • Android app Google Play
  • Download on the App Store
  • Download on the Amazon Appstore
  • Enterprise solutions
  • Claim your business
  • Developer resources
  • Jobs
  • Advertise with us
  • Terms of use
  • Privacy policy
  • Data and licenses
  • About our ads
  • Do not sell